Literature DB >> 19608990

Reversing stroke in the 2010s: lessons from Desmoteplase In Acute ischemic Stroke-2 (DIAS-2).

David S Liebeskind1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19608990      PMCID： PMC3058759          DOI： 10.1161/STROKEAHA.109.559682

Source DB:  PubMed          Journal:  Stroke        ISSN： 0039-2499            Impact factor:   7.914


× No keyword cloud information.
  10 in total

Review 1.  Collateral circulation.

Authors:  David S Liebeskind
Journal:  Stroke       Date:  2003-07-24       Impact factor: 7.914

2.  Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes.

Authors:  Marc Fisher; Daniel F Hanley; George Howard; Edward C Jauch; Steven Warach
Journal:  Stroke       Date:  2007-01-04       Impact factor: 7.914

3.  The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience.

Authors:  G H Guyatt; J L Keller; R Jaeschke; D Rosenbloom; J D Adachi; M T Newhouse
Journal:  Ann Intern Med       Date:  1990-02-15       Impact factor: 25.391

4.  Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset.

Authors:  Anthony J Furlan; Dirk Eyding; Gregory W Albers; Yasir Al-Rawi; Kennedy R Lees; Howard A Rowley; Christian Sachara; Mariola Soehngen; Steven Warach; Werner Hacke
Journal:  Stroke       Date:  2006-03-30       Impact factor: 7.914

Review 5.  Collateral therapeutics for cerebral ischemia.

Authors:  David S Liebeskind
Journal:  Expert Rev Neurother       Date:  2004-03       Impact factor: 4.618

6.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

Authors:  Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

7.  Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study.

Authors:  Werner Hacke; Anthony J Furlan; Yasir Al-Rawi; Antoni Davalos; Jochen B Fiebach; Franz Gruber; Markku Kaste; Leslie J Lipka; Salvador Pedraza; Peter A Ringleb; Howard A Rowley; Dietmar Schneider; Lee H Schwamm; Joaquin Serena Leal; Mariola Söhngen; Phil A Teal; Karin Wilhelm-Ogunbiyi; Max Wintermark; Steven Warach
Journal:  Lancet Neurol       Date:  2008-12-25       Impact factor: 44.182

8.  Impact of admission hyperglycemia on stroke outcome after thrombolysis: risk stratification in relation to time to reperfusion.

Authors:  José Alvarez-Sabín; Carlos A Molina; Marc Ribó; Juan F Arenillas; Joan Montaner; Rafael Huertas; Esteban Santamarina; Marta Rubiera
Journal:  Stroke       Date:  2004-10-07       Impact factor: 7.914

9.  Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials.

Authors:  Jeffrey L Saver; Gregory W Albers; Billy Dunn; Karen C Johnston; Marc Fisher
Journal:  Stroke       Date:  2009-05-28       Impact factor: 7.914

10.  MR mismatch profiles in patients with intracranial atherosclerotic stroke: a comprehensive approach comparing stroke subtypes.

Authors:  Suk Jae Kim; Jin Myoung Seok; Oh Young Bang; Gyeong-Moon Kim; Keon Ha Kim; Pyoung Jeon; Chin-Sang Chung; Kwang Ho Lee; Jeffry R Alger; David S Liebeskind
Journal:  J Cereb Blood Flow Metab       Date:  2009-04-15       Impact factor: 6.200
  10 in total
  9 in total

1.  Improved method for the preparation of a human cell-based, contact model of the blood-brain barrier.

Authors:  Be'eri Niego; Robert L Medcalf
Journal:  J Vis Exp       Date:  2013-11-12       Impact factor: 1.355

Review 2.  Desmoteplase: discovery, insights and opportunities for ischaemic stroke.

Authors:  Robert L Medcalf
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

3.  Use of telemedicine and other strategies to increase the number of patients that may be treated with intravenous thrombolysis.

Authors:  Gisele Sampaio Silva; Lee H Schwamm
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

Review 4.  Antithrombotic therapy for ischemic stroke: guidelines translated for the clinician.

Authors:  Anandi Krishnan; Renato D Lopes; John H Alexander; Richard C Becker; Larry B Goldstein
Journal:  J Thromb Thrombolysis       Date:  2010-04       Impact factor: 2.300

Review 5.  Collateral Status and Outcomes after Thrombectomy.

Authors:  Jin Soo Lee; Oh Young Bang
Journal:  Transl Stroke Res       Date:  2022-06-10       Impact factor: 6.829

Review 6.  Collateral Circulation in Ischemic Stroke: Assessment Tools and Therapeutic Strategies.

Authors:  Oh Young Bang; Mayank Goyal; David S Liebeskind
Journal:  Stroke       Date:  2015-10-08       Impact factor: 7.914

7.  Pharmacological and non-pharmacological recanalization strategies in acute ischemic stroke.

Authors:  Anita Frendl; László Csiba
Journal:  Front Neurol       Date:  2011-05-27       Impact factor: 4.003

Review 8.  Thrombolysis for acute ischaemic stroke.

Authors:  Joanna M Wardlaw; Veronica Murray; Eivind Berge; Gregory J del Zoppo
Journal:  Cochrane Database Syst Rev       Date:  2014-07-29

Review 9.  Do stroke models model stroke?

Authors:  Philipp Mergenthaler; Andreas Meisel
Journal:  Dis Model Mech       Date:  2012-11       Impact factor: 5.758
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.